非增强CT血肿扩大标志物与Andexanet反应:ANNEXa-I试验分析
该研究为ANNEXa-I试验的事后分析(n=434),评估非增强CT(NCCT)标志物在因子Xa抑制剂相关脑出血中预测血肿扩大(HE)的价值。72.1%患者存在至少一个NCCT标志物,31.8%发生HE;异质性密度、低密度和黑洞征与HE独立相关,andexanet对HE的效应在各NCCT标志物亚组中基本一致。
要点
- 异质性密度、低密度和黑洞征与因子Xa抑制剂相关脑出血的血肿扩大独立相关。
- andexanet对血肿扩大的效应在各NCCT标志物亚组中基本一致。
- NCCT标志物有助于识别因子Xa抑制剂相关脑出血中血肿扩大高风险患者。
核心结论
- NCCT标志物有助于识别因子Xa抑制剂相关脑出血中血肿扩大高风险患者。
- andexanet对血肿扩大的效应在各NCCT标志物亚组中基本一致。
研究设计与样本
- ANNEXa-I试验的事后分析,样本量n=434,评估因子Xa抑制剂相关脑出血的NCCT血肿扩大标志物。
主要发现
- 72.1%的患者存在至少一个NCCT标志物。
- 31.8%的患者发生血肿扩大,定义为血肿体积增加≥12.5 mL或≥35%。
- 异质性密度、低密度和黑洞征与血肿扩大独立相关。
关键数值与推荐
- 血肿扩大定义为血肿体积增加≥12.5 mL或≥35%。
- 至少一个NCCT标志物存在于72.1%的患者中。
临床怎么用
- 对于因子Xa抑制剂相关脑出血患者,可应用NCCT标志物识别血肿扩大高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this post hoc analysis of the ANNEXa-I trial (n = 434), we evaluated non-contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) -associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8%. Heterogeneous density, hypodensity, and the black hole sign were independently associated with HE. The effect of andexanet on HE was generally consistent across NCCT marker subgroups. These findings support the utility of NCCT markers for identifying patients at high risk of HE in FXai-associated ICH. ANN NEUROL 2026;100:979-983.
引用
- Tanaka K, Pensato U, Alshamrani M, et al. Non-contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: An Analysis from ANNEXa-I Trial. Ann Neurol. 2026. PMID: 42708556. doi:10.1002/ana.78347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。